Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | FABP4 | P15090 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | FADS1 | O60427 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4010775 | 0.86 | KMT2A (0.66) | MEN1KMT2AGAATSHRALDH1A1 | |
| SCHEMBL4008852 | 0.84 | MEN1 (0.63) | MEN1KMT2AGAATSHRALDH1A1 | |
| SCHEMBL12231092 | 0.82 | MEN1 (0.63) | MEN1KMT2AGAATSHRALDH1A1 | |
| SCHEMBL4511945 | 0.79 | TSHR (0.58) | MEN1KMT2AGAATSHRALDH1A1 | |
| SCHEMBL20219039 | 0.77 | TSHR (0.76) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4010777 | 0.76 | TSHR (0.54) | MEN1KMT2AGAATSHRALDH1A1 | |
| SCHEMBL16160985 | 0.76 | KMT2A (0.76) | MEN1KMT2AGAATSHRALDH1A1 | |
| SCHEMBL31023418 | 0.75 | TSHR (0.73) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4002460 | 0.75 | TSHR (0.73) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL15302068 | 0.74 | TSHR (1.00) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069286-B1 | INHIBITORS FOR GLYT-1 | HOFFMANN LA ROCHE (CH) | 2012-09-19 | — | — | EP | claimed |
| US-7589089-B2 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. (US) | 2009-09-15 | — | — | US | claimed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | claimed |
| EP-2069286-B1 | INHIBITORS FOR GLYT-1 | HOFFMANN LA ROCHE (CH) | 2012-09-19 | — | — | EP | disclosed |
| US-7589089-B2 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058331-A1 | Inhibitors for GlyT-1 | GLRA1, SLC1A2, AGXT | MEN1 2246/4885KMT2A 218/4885GAA 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.